Professor, Department of Clinical Pharmacology
Ruprecht-Karls University Heidelberg, Germany
Job Harenberg is Professor of Medicine and Haemostaseology and deputy director in the Department of Clinical Pharmacology Mannheim at the University of Heidelberg, Germany. He was appointed as Full Professor of Internal Medicine at the Faculty of Medicine Mannheim since 1991. He received his medical degree in 1975 from the Faculty of Medicine of the Ruprecht-Karls-University, Heidelberg, and achieved an habilitation in the field of Internal Medicine in 1984. Professor Harenberg has worked in thrombosis and haemostasis research and in the clinical treatment of patients for more than thirty years, and has published more than 200 peer-reviewed papers. He specializes in new antithrombotic agents for use in conventional and in new indications. He has several patents on new anticoagulants for diagnostic purposes. This year, he is organizing the 18th Glycosaminoglycan Symposium with Dr Benito Casu, which will be held at Villa Vigoni near Lake Como in Northern Italy.
Laboratory research: The current main topics of laboratory research are related to the development and validation of anticoagulant effects and determination of the concentration of new anticoagulants.
Clinical research: Determination of the anticoagulants heparins, oral direct factor Xa inhibitors, oral direct factor IIa inhibitors from plasma samples of patients treated with these anticoagulants. Participation in phase II, III and phase IV clinical trials of new anticoagulants in atrial fibrillation, unstable angina, thrombosis, pulmonary embolism, prophylaxis of thromboembolism in medical patients and in patients with malignancies. Investigator initiated trials in surgical and medical patients for prophylaxis of thromboembolism using oral factor Xa inhibitors and oral factor IIa inhibitors. Analysis of a relationship between the effect of anticoagulation with phenprocoumon (determined by the international normalized ratio) and personality traits in, analysis of personality traits in relation to the willingness of patients to switch from conventional to new anticoagulants. Metaanalysis of studie with new oral anticoagulants. Pharmacokinetics of a new oral anticoagulans and other new anticoagulants.